- Home
- MDV vs TLSI Comparison
MDV vs TLSI Comparison
Compare MDV & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDV
- TLSI
- Stock Information
- Founded
- MDV 2015
- TLSI 2010
- Country
- MDV United States
- TLSI United States
- Employees
- MDV N/A
- TLSI N/A
- Industry
- MDV Transportation Services
- TLSI Medical Specialities
- Sector
- MDV Consumer Discretionary
- TLSI Health Care
- Exchange
- MDV Nasdaq
- TLSI Nasdaq
- Market Cap
- MDV 147.6M
- TLSI 150.0M
- IPO Year
- MDV 2022
- TLSI N/A
- Fundamental
- Price
- MDV $14.87
- TLSI $4.90
- Analyst Decision
- MDV
- TLSI Strong Buy
- Analyst Count
- MDV 0
- TLSI 5
- Target Price
- MDV N/A
- TLSI $10.90
- AVG Volume (30 Days)
- MDV 38.1K
- TLSI 110.1K
- Earning Date
- MDV 11-05-2025
- TLSI 08-12-2025
- Dividend Yield
- MDV 7.81%
- TLSI N/A
- EPS Growth
- MDV N/A
- TLSI N/A
- EPS
- MDV N/A
- TLSI N/A
- Revenue
- MDV $47,273,000.00
- TLSI $35,990,000.00
- Revenue This Year
- MDV $1.72
- TLSI $56.79
- Revenue Next Year
- MDV $3.86
- TLSI $54.15
- P/E Ratio
- MDV N/A
- TLSI N/A
- Revenue Growth
- MDV N/A
- TLSI 45.50
- 52 Week Low
- MDV $13.62
- TLSI $3.42
- 52 Week High
- MDV $18.11
- TLSI $5.88
- Technical
- Relative Strength Index (RSI)
- MDV 47.77
- TLSI 52.20
- Support Level
- MDV $15.00
- TLSI $4.80
- Resistance Level
- MDV $15.40
- TLSI $5.24
- Average True Range (ATR)
- MDV 0.30
- TLSI 0.32
- MACD
- MDV -0.03
- TLSI 0.01
- Stochastic Oscillator
- MDV 19.43
- TLSI 50.40
About MDV Modiv Industrial Inc. Class C
Modiv Industrial Inc is a pioneer in the direct-to-consumer commercial real estate product industry. It provides individual investors access to real estate and real estate-related investments designed to provide both income and long-term growth. The Company has invested in single-tenant income-producing properties. Its current business consists of owning, managing, operating, leasing, acquiring, investing in and disposing of commercial real estate assets utilized for industrial manufacturing, as well as a few non-core assets. All of the company's consolidated revenues are derived from company's consolidated real estate properties.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.